ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ACOR Acorda Therapeutics Inc

13.211
1.30 (10.92%)
After Hours
Last Updated: 16:36:54
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,617
Bid Price 13.98
Ask Price 15.00
News -
Day High 13.315

Low
8.978

52 Week Range

High
24.196

Day Low 11.82
Company Name Stock Ticker Symbol Market Type
Acorda Therapeutics Inc ACOR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.30 10.92% 13.211 16:36:54
Open Price Low Price High Price Close Price Prev Close
12.29 11.82 13.315 13.211 11.91
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
93 4,617 $ 12.43 $ 57,371 - 8.978 - 24.196
Last Trade Time Type Quantity Stock Price Currency
16:41:10 5 $ 13.98 USD

Acorda Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
16.41M 1.24M - 131.12M -65.92M -53.07 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Acorda Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ACOR Message Board. Create One! See More Posts on ACOR Message Board See More Message Board Posts

Historical ACOR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.5013.31511.81112.083,1060.7115.69%
1 Month14.0914.7511.81112.874,525-0.879-6.24%
3 Months14.4518.0011.81114.673,786-1.24-8.57%
6 Months14.78518.009.1012.694,963-1.57-10.65%
1 Year10.81824.1968.97816.86215,7952.3922.12%
3 Years98.40127.205.22227.86703,823-85.19-86.57%
5 Years1,568.401,623.605.222155.781,346,309-1,555.19-99.16%

Acorda Therapeutics Description

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.

Your Recent History

Delayed Upgrade Clock